ESMO 2021 | Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer

Evanthia T. Roussos Torres, MD, PhD, Keck School of Medicine of USC, Los Angeles, CA, discusses the results of a study evaluating the combination of entinostat, nivolumab and ipilimumab in patients with advanced HER2-negative breast cancer. At the recomended Phase II dose, this combinatorial approach was associated with expected immune-related adverse events in advanced HER2-negative breast cancer. An overall response rate of 30% suggests this combination should be evaluated further. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.